Sports
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago, Illinois.
About this update from Eli Lilly And Company
[{"type":"text","content":"Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program ","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"Investigator-initiated study of Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma also selected for the Plenary Session","length":147,"tagName":"p","attribs":{}},{"type":"text","content":"Kelonia Therapeutics, which Lilly has agreed to acquire, will present updated data for its BCMA-targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myeloma","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"Additional Lilly presentations include the first clinical results for an investigational ADC targeting Nectin-4 in patients with advanced urothelial carcinoma and data from programs across lung, breast and blood cancers ","length":225,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago, Illinois.","length":285,"tagName":"p"},{"type":"text","content":"Data at ASCO include two Plenary Session presentations, featuring primary event-free survival results from the Phase 3 LIBRETTO-432 study of adjuvant Retevmo (selpercatinib) in rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and an investigator-initiated Phase 3 study, SARC041, evaluating Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma. Additional data include an oral presentation of initial results of an investigational antibody drug conjugate (ADC) targeting Nectin-4 in patients with advanced or metastatic urothelial carcinoma, and data from programs in lung, breast and blood cancers. Updated data from Kelonia Therapeutics' Phase 1 inMMyCAR study of an anti-B-cell maturation antigen (BCMA) targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myeloma will also be presented in an oral session. Lilly's proposed acquisition of Kelonia Therapeutics was previously announced and is pending transaction close.","...